
Novan Inc (AKA: Novan Therapeutics) Profile last edited on: 1/17/2024
CAGE: 4C5W6
UEI: JVY7LPMCSFM8
Business Identifier: Nitric oxide-based drug delivery Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
4105 Hopson Road
Morrisville, NC 27560
Morrisville, NC 27560
(919) 485-8080 |
info@novantherapeutics.com |
www.novantherapeutics.com |
Location: Single
Congr. District: 04
County: Wake
Congr. District: 04
County: Wake
Public Profile
Durham-based Novan Inc. sells all assets, files for bankruptcy. Novan is a publicly traded, clinical-stage drug development company (NASDA:NOVN) developing deliverable products that tap into the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. With management's goal defined as being a leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies using the firm's proprietary nitric oxide-based technology platform, NITRICIL to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications. With a particular focus on treatment of dermatological and oncovirus-mediated diseases, the Companys core technologies solve the previous delivery issues with nitric oxide by storing the gaseous species as an engineered molecule that allows for the "timed release" of nitric oxide in short- or long-term healthcare applications. By storing nitric oxide as part of an engineered molecule, the characteristics of the framework can be controlled to tune the level of nitric oxide storage, the rate of nitric oxide release, and the molecule size to target nitric oxide delivery. The result is stabilized, drug-able nitric oxide.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
100-149Revenue Range
10M-15MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : NOVNIP Holdings
75-99Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $1,346,915 | |
Project Title: Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women | ||||
2016 | 2 | NIH | $2,283,144 | |
Project Title: Improving Host Response to Implantable Glucose Sensors Via Nitric Oxide Release | ||||
2013 | 2 | NSF | $1,137,187 | |
Project Title: Scale-up Manufacturing of Nitric Oxide Nanotechnology for Healthcare Infections | ||||
2012 | 2 | NIH | $592,972 | |
Project Title: Nitric Oxide-Releasing Intranasal Gel to Decolonize Biofilm-Embedded S. Aureus | ||||
2012 | 2 | NIH | $3,068,681 | |
Project Title: Nitric Oxide-Releasing Antibacterial Wound Dressing |
Key People / Management
Donald Hamilton -- CEO
Nathan A Stasko -- Co-Founder, President and Chief Executive Officer
Susanne Bauman
Carri Geer
Cari Green -- Associate Director, Contracts And Grants
Stan Hollenbach -- VP of Research and Nonclinical Development
Tim O'Sullivan -- VP of Intellectual Capital
Richard Peterson -- Chief Financial Officer
Benjamin Joseph Privett
M Joyce Rico -- Chief Medical Officer
Welsey Storm
Nathan A Stasko -- Co-Founder, President and Chief Executive Officer
Susanne Bauman
Carri Geer
Cari Green -- Associate Director, Contracts And Grants
Stan Hollenbach -- VP of Research and Nonclinical Development
Tim O'Sullivan -- VP of Intellectual Capital
Richard Peterson -- Chief Financial Officer
Benjamin Joseph Privett
M Joyce Rico -- Chief Medical Officer
Welsey Storm
Company News
Jul
18
2023
|
Durham-based Novan Inc. sells all assets, files for bankruptcy |
Sep
20
2019
|
Novan lands $1.1M federal grant for cancer research |
Oct
26
2016
|
What's Next for Novan After Its IPO? |
Mar
30
2015
|
Novan Secures $50 Million Private Financing |
Mar
10
2014
|
Neal Hunter-backed startup raises $3.5M |